Skip to main content

Table 3 Grade ≥ 3 adverse events

From: Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

Grade ≥ 3 adverse events

2019 Royal Marsden % (n = 50) (%)

2017 study

(n = 28) (%)

2013 GRID study

(n = 132) (%)

All grade ≥ 3 AEs

23 (46)

12 (42.9)

81 (61.4)

PPE

9 (18)

5 (17.9)

26 (19.7)

Fatigue

7 (14)

5 (17.9)

3 (2.3)

Hypertension

4 (8)

2 (7.1)

31 (23.5)

Hepatotoxicity

1 (2)

0 (0)

1 (0.8)

Diarrhoea

1 (2)

2 (7.1)

7 (5.3)

Arthralgia

1 (2)

0 (0)

1 (1%)